Melanin-concentrating hormone signaling: MCHR1/MCHR2 laboratory assay design

1) Control the cyclic ligand as a defined chemical species

Mammalian MCH is a nonadecapeptide whose Cys7–Cys16 intramolecular disulfide constrains a ten-residue ring. That linkage is part of the pharmacophore, not a decorative structural detail. A preparation with the expected average mass can still contain reduced peptide, intermolecular disulfide products, oxidized side chains, or incorrectly assigned material. Record the exact sequence, disulfide specification, terminal chemistry, counterion, purity method, water content, concentration method, lot, storage temperature, and freeze–thaw history.

Confirm intact mass and chromatographic homogeneity under conditions able to resolve reduced, cyclic, and aggregated species. A reduced-versus-nonreduced comparison is useful, but analytical agreement should be paired with receptor-dependent function. Qualify each lot using a complete concentration–response curve in a sequence-verified MCHR1 line, with a reference lot on the same plate. Include parental cells and a receptor-independent pathway control to expose nonspecific effects or general loss of cell responsiveness.

Peptide adsorption can matter at the low concentrations used for high-affinity receptors. Define plate material, carrier protein, solvent, incubation time, and transfer count. Measure peptide recovery from representative assay medium when unexplained potency shifts appear. Avoid assuming that a nominal stock concentration equals the concentration delivered to cells, particularly after repeated dilution through unvalidated plasticware.

2) Assign responses with matched single-receptor systems

The receptor first called SLC-1 or GPR24 is now designated MCHR1. Lembo and colleagues deorphanized rat SLC-1 by showing activation by nanomolar MCH and Gi/o coupling.^[1] A second human receptor, initially called SLT and now MCHR2, was cloned from hippocampal cDNA; MCH activated it at subnanomolar concentrations in transfected CHO cells.^[2] Historical names should be mapped explicitly in protocols and data files so that receptor identity is not lost when comparing older studies.

Natural MCH activates both human subtypes. Therefore, an MCH response in a mixed or native preparation is not subtype evidence. Build MCHR1-only and MCHR2-only lines in the same host background, alongside parental and receptor-knockout controls. Sequence-verify the complete open reading frame, document tag placement, integration method, passage range, and culture conditions, and quantify surface receptor rather than relying on total lysate expression.

Receptor density changes apparent potency and maximal response in amplified assays. Match surface abundance where subtype comparisons are intended, or deliberately titrate receptor expression and show that conclusions survive more than one density. Genetic loss and wild-type rescue provide the strongest attribution. Antagonists can support the assignment only after their subtype selectivity, equilibration time, and off-target effects are validated in the same cellular background.

3) Separate Gi/o signaling from engineered calcium amplification

MCHR1 can couple to Gi/o, making inhibition of forskolin-stimulated cAMP a mechanistically relevant primary assay. Establish a forskolin concentration within the reporter’s dynamic range, acquire a full time course, and include a receptor-independent control for adenylyl-cyclase competence. Pertussis toxin sensitivity can support Gi/o involvement, but toxin lot, concentration, exposure time, and cell viability require validation. A toxin-sensitive endpoint is pathway evidence, not proof of direct ligand binding.

Calcium mobilization is also commonly observed in recombinant systems, either through native coupling or an engineered promiscuous G protein. It is fast and scalable but highly sensitive to receptor reserve, dye loading, cell density, temperature, injection mixing, and intracellular-store capacity. Report peak and integrated signal with predefined windows. If Gα16, Gqi, or another coupling adapter is used, state it prominently: the assay measures an engineered transduction route and should not be described as the receptor’s native coupling preference.

Use a proximal orthogonal readout such as G-protein recruitment, heterotrimer dissociation, or nucleotide exchange to connect receptor activation to downstream cAMP or calcium. Then examine ERK phosphorylation or transcriptional outputs only with an early time course and receptor-null controls. Late downstream signals can include feedback, secondary transmitters, or stress responses and cannot substitute for a proximal mechanism.

For subtype comparisons, run MCHR1 and MCHR2 on the same plate with equivalent receptor surface abundance and the same detection technology. Compare full curves, not one saturating concentration. Report operational parameters such as baseline, maximal effect, Hill slope, and uncertainty; apparent EC50 values from different receptor densities or different coupling adapters are not direct measures of binding affinity.

4) Treat binding probes as new ligands that require qualification

Quantitative binding provides an essential counterweight to amplified functional assays. Drozdz and colleagues designed an iodination-compatible MCH analogue and observed high-affinity, saturable binding in several cell lines; their G4F-7 saturation analysis estimated a KD of 1.18 × 10⁻¹⁰ M and approximately 1,090 sites per cell.^[3] Those values belong to that probe and preparation, not to every MCH assay, but the study demonstrates the value of saturation, competition, and specificity controls.

Radiolabeling or fluorescent modification can change affinity, efficacy, adsorption, or stability. Establish probe purity, specific activity or degree of labeling, receptor-dependent binding, nonspecific binding, association and dissociation kinetics, and competition by unlabeled MCH. Define nonspecific binding using an independently justified excess of competitor, and verify that the concentration does not damage cells or alter membrane integrity.

Durieux and colleagues developed the iodinated peptide analogue S36057 for MCHR1 membranes. It retained agonist activity and gave subnanomolar saturation and kinetic affinity estimates, while also illustrating that a modified, truncated ligand can outperform an earlier tracer in stability and apparent affinity.^[4] The practical lesson is not that one tracer is universally preferred; it is that each probe must be characterized as its own pharmacological reagent.

Use saturation experiments to estimate affinity and capacity, competition experiments to compare unlabeled ligands, and kinetic experiments to test whether equilibrium was reached. Depletion becomes important when receptor abundance is not negligible relative to tracer concentration. Record membrane protein, cell number, temperature, incubation time, filtration or wash conditions, and analysis model. Residual plots and replicate curves should accompany fitted parameters.

5) Make species selection part of the hypothesis

MCHR2 creates an unusually consequential species problem. Tan and colleagues found that rat, mouse, hamster, guinea pig, and rabbit either lack a functional MCHR2 receptor or carry a nonfunctional pseudogene, whereas dog, ferret, and rhesus receptors included functional MCHR2 alongside MCHR1.^[5] A conventional rodent preparation therefore cannot test the contribution of endogenous MCHR2, no matter how sensitive the endpoint.

Before moving from a human recombinant assay to native material, confirm the receptor gene, intact coding sequence, transcript, and cell-type distribution in the exact species and tissue. For a rodent experiment, frame conclusions as MCHR1 biology unless a validated heterologous MCHR2 construct is intentionally introduced. Conversely, a species with both receptors still requires subtype-resolving perturbations because the presence of both genes does not establish which receptor generated a measured response.

Species differences also complicate antagonist validation and peptide potency comparisons. Cross-test reference ligands against cloned receptors from each study species under matched conditions. Keep receptor sequence, host cell, surface abundance, assay temperature, and coupling system visible in the dataset. A potency rank observed at human MCHR2 should not be transferred to a different ortholog without measurement.

6) Resolve receptor trafficking without confusing ligand uptake

Fluorescent MCH can support localization and binding experiments, but intracellular fluorescence does not by itself prove receptor internalization. Labeled peptide can adhere to the membrane, enter through fluid-phase uptake, or separate from its fluorophore. Pair ligand tracking with an independently labeled receptor or a validated extracellular epitope assay, and include parental cells, excess unlabeled MCH, free-dye or linker controls, low-temperature binding, and surface-quenching or acid-wash steps.

For receptor internalization, distinguish surface loss, endosomal accumulation, degradation, and recycling. Predefine segmentation, background subtraction, acquisition interval, exposure, and photobleaching correction. Demonstrate that an epitope or fluorescent receptor tag preserves ligand affinity and signaling. Compare continuous exposure with pulse–wash conditions, and measure functional recovery after defined wash intervals rather than inferring resensitization from microscopy alone.

Ligand integrity should be monitored during long incubations. Sample medium at the beginning and end and assess intact peptide recovery using a suitable chromatographic or mass-spectrometric method. If signal persists after washout, test for retained surface ligand, internalized ligand–receptor complexes, slow dissociation, and downstream pathway memory as separate hypotheses.

7) A reproducible MCH assay workflow

1. Lock ligand identity. Record sequence, Cys7–Cys16 linkage, formulation, concentration method, storage, and analytical recovery.
2. Build matched receptor backgrounds. Use sequence-verified MCHR1 and MCHR2 constructs, a common host, quantified surface expression, and parental cells.
3. Establish receptor causality. Require loss in receptor-null cells and restoration by wild-type rescue before assigning a subtype.
4. Triangulate signaling. Combine a proximal G-protein measure with cAMP or calcium and disclose any engineered coupling adapter.
5. Qualify binding probes. Measure affinity, kinetics, nonspecific binding, stability, and retained agonism for every labeled analogue.
6. Audit species biology. Verify whether functional MCHR2 exists before interpreting native experiments.
7. Resolve time and location. Separate binding, internalization, recycling, ligand persistence, and pathway recovery with independent measurements.

A rigorous MCH study keeps chemistry, receptor subtype, signaling pathway, and species biology separate until the data connect them. That design prevents an amplified calcium transient, a labeled peptide image, or a rodent endpoint from carrying more mechanistic weight than it can support.